"Fenofibrate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood.
| Descriptor ID |
D011345
|
| MeSH Number(s) |
D02.241.081.114.968.500.625 D02.355.726.305.625 D02.455.426.559.389.134.750 D02.455.426.559.389.657.654.305.625 D02.522.223.750
|
| Concept/Terms |
Fenofibrate- Fenofibrate
- Phenofibrate
- Procetofene
- Procetofen
Apo-Feno-Micro- Apo-Feno-Micro
- Apo Feno Micro
- Apo-Fenofibrate
- Apo Fenofibrate
Lipanthyl- Lipanthyl
- Lipantil
- Fenofibrat FPh
- Lipidil
- Secalip
- Supralip
- Fénofibrate Debat
- Debat, Fénofibrate
- Lipidil-Ter
- Lipidil Ter
|
Below are MeSH descriptors whose meaning is more general than "Fenofibrate".
Below are MeSH descriptors whose meaning is more specific than "Fenofibrate".
This graph shows the total number of publications written about "Fenofibrate" by people in this website by year, and whether "Fenofibrate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2005 | 3 | 0 | 3 |
| 2006 | 1 | 1 | 2 |
| 2008 | 3 | 0 | 3 |
| 2009 | 2 | 1 | 3 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2012 | 3 | 1 | 4 |
| 2014 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fenofibrate" by people in Profiles.
-
Fenofibrate reduces intestinal damage and improves intestinal recovery following intestinal ischemia-reperfusion injury in a rat. Pediatr Surg Int. 2016 Dec; 32(12):1193-1200.
-
Combination therapy with statins: who benefits? Endocrinol Metab Clin North Am. 2014 Dec; 43(4):993-1006.
-
Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arterioscler Thromb Vasc Biol. 2014 Jun; 34(6):1298-306.
-
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther. 2012 Aug; 26(4):349-58.
-
Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J Clin Lipidol. 2013 Mar-Apr; 7(2):102-8.
-
One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response. Am J Cardiovasc Drugs. 2012 Apr 01; 12(2):117-25.
-
Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies. J Clin Lipidol. 2012 Nov-Dec; 6(6):534-44.
-
Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (= 2 mg/L). cmb@bcm.tmc.edu. J Clin Lipidol. 2011 Sep-Oct; 5(5):401-7.
-
Do fibrates truly preserve kidney function? Nat Rev Endocrinol. 2011 Mar; 7(3):130-1.
-
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs. 2010; 10(2):73-84.